Glucose-dependent insulinotropic polypeptide signaling in pancreatic β-cells and adipocytes
- PMID: 24843552
- PMCID: PMC4020726
- DOI: 10.1111/j.2040-1124.2012.00196.x
Glucose-dependent insulinotropic polypeptide signaling in pancreatic β-cells and adipocytes
Abstract
Glucose-dependent insulinotropic polypeptide (GIP) was the first incretin to be identified. In addition to stimulating insulin secretion, GIP plays regulatory roles in the maintenance, growth and survival of pancreatic islets, as well as impacting on adipocyte function. The current review focuses on the intracellular signaling pathways by which GIP contributes to the regulation of β-cell secretion and survival, and adipocyte differentiation and lipogenesis. Studies on signaling underlying the insulinotropic actions of the incretin hormones have largely been carried out with glucagon-like peptide-1. They have provided evidence for contributions by both protein kinase A (PKA) and exchange protein directly activated by cyclic adenosine monophosphate (EPAC2), and their probable role in GIP signaling is discussed. Recent studies have shown that inhibition of the kinase apoptosis signal-regulating kinase 1 (ASK1) by GIP plays a key role in reducing mitochondria-induced apoptosis in β-cells through protein kinase B (PKB)-mediated pathways, and that GIP-induced post-translational modification of voltage- dependent K(+) (Kv) channels also contributes to its prosurvival role. Through regulation of gene expression, GIP tips the balance between pro- and anti-apoptotic members of the B-cell lymphoma-2 (Bcl-2) protein family towards β-cell survival. GIP also plays important roles in the differentiation of pre-adipocytes to adipocytes, and in the regulation of lipoprotein lipase expression and lipogenesis. These events involve interactions between GIP, insulin and resistin signaling pathways. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2012.00196.x, 2012).
Keywords: Apoptosis; Glucose‐dependent insulinotropic polypeptide; Incretin.
Figures



Similar articles
-
Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes.J Biol Chem. 2007 Nov 23;282(47):34139-47. doi: 10.1074/jbc.M704896200. Epub 2007 Sep 20. J Biol Chem. 2007. PMID: 17890220
-
Resistin knockout mice exhibit impaired adipocyte glucose-dependent insulinotropic polypeptide receptor (GIPR) expression.Diabetes. 2013 Feb;62(2):471-7. doi: 10.2337/db12-0257. Epub 2012 Sep 21. Diabetes. 2013. PMID: 23002036 Free PMC article.
-
Pancreatic β-cell prosurvival effects of the incretin hormones involve post-translational modification of Kv2.1 delayed rectifier channels.Cell Death Differ. 2012 Feb;19(2):333-44. doi: 10.1038/cdd.2011.102. Epub 2011 Aug 5. Cell Death Differ. 2012. PMID: 21818121 Free PMC article.
-
GIP and GLP-1, the two incretin hormones: Similarities and differences.J Diabetes Investig. 2010 Apr 22;1(1-2):8-23. doi: 10.1111/j.2040-1124.2010.00022.x. J Diabetes Investig. 2010. PMID: 24843404 Free PMC article. Review.
-
Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP).Vitam Horm. 2009;80:409-71. doi: 10.1016/S0083-6729(08)00615-8. Vitam Horm. 2009. PMID: 19251046 Review.
Cited by
-
The study of metabolic improvement by nutritional intervention controlling endogenous GIP (Mini Egg study): a randomized, cross-over study.Nutr J. 2019 Sep 2;18(1):52. doi: 10.1186/s12937-019-0472-0. Nutr J. 2019. PMID: 31477157 Free PMC article. Clinical Trial.
-
Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data.Curr Obes Rep. 2025 Apr 11;14(1):34. doi: 10.1007/s13679-025-00623-1. Curr Obes Rep. 2025. PMID: 40210807 Free PMC article. Review.
-
Gs/Gq signaling switch in β cells defines incretin effectiveness in diabetes.J Clin Invest. 2020 Dec 1;130(12):6639-6655. doi: 10.1172/JCI140046. J Clin Invest. 2020. PMID: 33196462 Free PMC article.
-
The evolution of the therapeutic concept 'GIP receptor antagonism'.Front Endocrinol (Lausanne). 2025 May 21;16:1570603. doi: 10.3389/fendo.2025.1570603. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40469445 Free PMC article. Review.
-
Increased plasma levels of glucose-dependent insulinotropic polypeptide are associated with decreased postprandial energy expenditure after modern Japanese meals.Eur J Nutr. 2017 Jun;56(4):1693-1705. doi: 10.1007/s00394-016-1216-y. Epub 2016 Apr 25. Eur J Nutr. 2017. PMID: 27112963 Free PMC article. Clinical Trial.
References
-
- Brubaker PL. The glucagon‐like peptides: pleiotropic regulators of nutrient homeostasis. Ann N Y Acad Sci 2006; 1070: 10–26 - PubMed
-
- Drucker DJ, Nauck MA. The incretin system: glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696–1705 - PubMed
-
- McIntosh CHS, Widenmaier S, Kim S‐J. Glucose‐dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). Vitam Horm 2009; 80: 409–471 - PubMed
-
- McIntosh CHS, Widenmaier S, Kim S‐J. Pleiotropic actions of the incretin hormones. Vitam Horm 2010; 84: 21–79 - PubMed
-
- Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009; 297: 127–136 - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous